657 related articles for article (PubMed ID: 29619863)
1. An overview of treatment strategies for Hutchinson-Gilford Progeria syndrome.
Harhouri K; Frankel D; Bartoli C; Roll P; De Sandre-Giovannoli A; Lévy N
Nucleus; 2018 Jan; 9(1):246-257. PubMed ID: 29619863
[TBL] [Abstract][Full Text] [Related]
2. Cellular stress and AMPK activation as a common mechanism of action linking the effects of metformin and diverse compounds that alleviate accelerated aging defects in Hutchinson-Gilford progeria syndrome.
Finley J
Med Hypotheses; 2018 Sep; 118():151-162. PubMed ID: 30037605
[TBL] [Abstract][Full Text] [Related]
3. Identification of mitochondrial dysfunction in Hutchinson-Gilford progeria syndrome through use of stable isotope labeling with amino acids in cell culture.
Rivera-Torres J; Acín-Perez R; Cabezas-Sánchez P; Osorio FG; Gonzalez-Gómez C; Megias D; Cámara C; López-Otín C; Enríquez JA; Luque-García JL; Andrés V
J Proteomics; 2013 Oct; 91():466-77. PubMed ID: 23969228
[TBL] [Abstract][Full Text] [Related]
4. MG132-induced progerin clearance is mediated by autophagy activation and splicing regulation.
Harhouri K; Navarro C; Depetris D; Mattei MG; Nissan X; Cau P; De Sandre-Giovannoli A; Lévy N
EMBO Mol Med; 2017 Sep; 9(9):1294-1313. PubMed ID: 28674081
[TBL] [Abstract][Full Text] [Related]
5. Epigenetic involvement in Hutchinson-Gilford progeria syndrome: a mini-review.
Arancio W; Pizzolanti G; Genovese SI; Pitrone M; Giordano C
Gerontology; 2014; 60(3):197-203. PubMed ID: 24603298
[TBL] [Abstract][Full Text] [Related]
6. Inhibiting farnesylation of progerin prevents the characteristic nuclear blebbing of Hutchinson-Gilford progeria syndrome.
Capell BC; Erdos MR; Madigan JP; Fiordalisi JJ; Varga R; Conneely KN; Gordon LB; Der CJ; Cox AD; Collins FS
Proc Natl Acad Sci U S A; 2005 Sep; 102(36):12879-84. PubMed ID: 16129833
[TBL] [Abstract][Full Text] [Related]
7. MG132 Induces Progerin Clearance and Improves Disease Phenotypes in HGPS-like Patients' Cells.
Harhouri K; Cau P; Casey F; Guedenon KM; Doubaj Y; Van Maldergem L; Mejia-Baltodano G; Bartoli C; De Sandre-Giovannoli A; Lévy N
Cells; 2022 Feb; 11(4):. PubMed ID: 35203262
[TBL] [Abstract][Full Text] [Related]
8. Molecular insights into the premature aging disease progeria.
Vidak S; Foisner R
Histochem Cell Biol; 2016 Apr; 145(4):401-17. PubMed ID: 26847180
[TBL] [Abstract][Full Text] [Related]
9. Presence and distribution of progerin in HGPS cells is ameliorated by drugs that impact on the mevalonate and mTOR pathways.
Clements CS; Bikkul MU; Ofosu W; Eskiw C; Tree D; Makarov E; Kill IR; Bridger JM
Biogerontology; 2019 Jun; 20(3):337-358. PubMed ID: 31041622
[TBL] [Abstract][Full Text] [Related]
10. Status of treatment strategies for Hutchinson-Gilford progeria syndrome with a focus on prelamin: A posttranslational modification.
Chen X; Yao H; Andrés V; Bergo MO; Kashif M
Basic Clin Pharmacol Toxicol; 2022 Oct; 131(4):217-223. PubMed ID: 35790078
[TBL] [Abstract][Full Text] [Related]
11. Hutchinson-Gilford Progeria Syndrome (Hgps) and Application of Gene Therapy Based Crispr/Cas Technology as A Promising Innovative Treatment Approach.
Rajeev M; Ratan C; Krishnan K; Vijayan M
Recent Pat Biotechnol; 2021; 15(4):266-285. PubMed ID: 34602042
[TBL] [Abstract][Full Text] [Related]
12. Farnesyltransferase inhibitor and rapamycin correct aberrant genome organisation and decrease DNA damage respectively, in Hutchinson-Gilford progeria syndrome fibroblasts.
Bikkul MU; Clements CS; Godwin LS; Goldberg MW; Kill IR; Bridger JM
Biogerontology; 2018 Dec; 19(6):579-602. PubMed ID: 29907918
[TBL] [Abstract][Full Text] [Related]
13. Pharmacotherapy to gene editing: potential therapeutic approaches for Hutchinson-Gilford progeria syndrome.
Saxena S; Kumar S
Geroscience; 2020 Apr; 42(2):467-494. PubMed ID: 32048129
[TBL] [Abstract][Full Text] [Related]
14. Hutchinson-Gilford Progeria Syndrome: Cellular Mechanisms and Therapeutic Perspectives.
Cisneros B; García-Aguirre I; De Ita M; Arrieta-Cruz I; Rosas-Vargas H
Arch Med Res; 2023 Jul; 54(5):102837. PubMed ID: 37390702
[TBL] [Abstract][Full Text] [Related]
15. Emerging candidate treatment strategies for Hutchinson-Gilford progeria syndrome.
Strandgren C; Revêchon G; Sola-Carvajal A; Eriksson M
Biochem Soc Trans; 2017 Dec; 45(6):1279-1293. PubMed ID: 29127216
[TBL] [Abstract][Full Text] [Related]
16. Vitamin D receptor signaling improves Hutchinson-Gilford progeria syndrome cellular phenotypes.
Kreienkamp R; Croke M; Neumann MA; Bedia-Diaz G; Graziano S; Dusso A; Dorsett D; Carlberg C; Gonzalo S
Oncotarget; 2016 May; 7(21):30018-31. PubMed ID: 27145372
[TBL] [Abstract][Full Text] [Related]
17. The Molecular and Cellular Basis of Hutchinson-Gilford Progeria Syndrome and Potential Treatments.
Batista NJ; Desai SG; Perez AM; Finkelstein A; Radigan R; Singh M; Landman A; Drittel B; Abramov D; Ahsan M; Cornwell S; Zhang D
Genes (Basel); 2023 Feb; 14(3):. PubMed ID: 36980874
[TBL] [Abstract][Full Text] [Related]
18. Incomplete processing of mutant lamin A in Hutchinson-Gilford progeria leads to nuclear abnormalities, which are reversed by farnesyltransferase inhibition.
Glynn MW; Glover TW
Hum Mol Genet; 2005 Oct; 14(20):2959-69. PubMed ID: 16126733
[TBL] [Abstract][Full Text] [Related]
19. Progerin impairs chromosome maintenance by depleting CENP-F from metaphase kinetochores in Hutchinson-Gilford progeria fibroblasts.
Eisch V; Lu X; Gabriel D; Djabali K
Oncotarget; 2016 Apr; 7(17):24700-18. PubMed ID: 27015553
[TBL] [Abstract][Full Text] [Related]
20. Towards delineating the chain of events that cause premature senescence in the accelerated aging syndrome Hutchinson-Gilford progeria (HGPS).
Dreesen O
Biochem Soc Trans; 2020 Jun; 48(3):981-991. PubMed ID: 32539085
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
